Ribo Life Science Achieves Important Listing Milestone
Ribo Life Science Co., Ltd. (06938.HK), a prominent name in small interfering RNA (siRNA) therapeutics, has recently made a significant move by listing on the Main Board of the Hong Kong Stock Exchange. This remarkable achievement serves as a pivotal moment in enhancing the visibility and growth potential of biopharmaceutical enterprises in the siRNA sector.
Overview of the Global Offering and Its Reception
In a successful global offering, Ribo Life Science issued a total of 31,610,400 shares, priced at HKD 57.97 each. The gross proceeds from this offering exceeded 1.8 billion Hong Kong dollars, showcasing robust investor interest, reflected in the offering’s more than 100 times oversubscription. International Placing also demonstrated strong demand, with oversubscription rates reaching 16.7 times, indicating a high level of confidence in both the siRNA sector and Ribo's unique capabilities.
The Impact of Cornerstone Investments
The offering attracted attention from 12 cornerstone investors including notable organizations such as Arc Avenue, Ivy Rock, Springs Capital, and Taikang Life Insurance. Their involvement highlights the strong faith leading institutions have in Ribo's future. This trust not only signifies the anticipated growth of the SiRNA field but also underlines the company's potential to develop impactful therapeutics globally.
Statements from Key Leadership
Dr. Zicai Liang, the Founder, Chairman, and CEO of Ribo Life Science, expressed his gratitude towards the global investment community. He remarked, "Listing on the Hong Kong Stock Exchange marks a significant milestone for Ribo. Our focus now is on leveraging international capital to fast-track the global clinical development of siRNA therapeutics, thus strengthening our ability to provide patients with cutting-edge therapies while enhancing shareholder value."
Utilization of IPO Proceeds
The proceeds from the IPO are strategically allocated to support four essential areas: advancing global multicenter clinical trials for core products, facilitating preclinical and clinical development of the company’s pipeline, iterating on siRNA delivery technologies, and replenishing operational capital for routine corporate purposes. This investment strategy will ensure that Ribo continues to thrive in a competitive market while meeting the needs of patients.
Innovative R&D Foundations
Ribo has committed to building a fully integrated research and development (R&D) platform underscored by independent intellectual property rights. Their innovative RiboGalSTAR™ delivery technology has already led to the advancement of several products into Phase II clinical trials. With R&D centers established in major locations such as Suzhou, Beijing, and Gothenburg, Sweden, Ribo has created a global network capable of supporting comprehensive drug development processes.
Fostering Future Growth and Development
The company's successful entry into capital markets was supported by China International Capital Corporation and Citigroup, who played critical roles as joint sponsors. Their expertise facilitated Ribo's venture into this new financial landscape, paving the way for future innovation and development in siRNA therapeutics.
About Ribo Life Science
Suzhou Ribo Life Science Co., Ltd. (06938.HK) is dedicated to developing and commercializing cutting-edge siRNA therapeutics. The company is driven by proprietary technology platforms that help address major disease areas, including cardiovascular, metabolic, liver, and kidney diseases. With a commitment to continuous innovation, Ribo Life Science seeks to provide groundbreaking treatment solutions to enhance patient outcomes globally.
Frequently Asked Questions
What is the main focus of Ribo Life Science?
Ribo Life Science focuses on developing small interfering RNA (siRNA) therapeutics to treat various diseases.
How much did Ribo raise through its IPO?
Ribo raised over 1.8 billion Hong Kong dollars in its global offering.
Who were some major investors in Ribo's IPO?
Notable cornerstone investors include Arc Avenue, Ivy Rock, and Taikang Life Insurance.
What are the key areas for future funding utilization?
Funds will support clinical trials, pipeline development, technology enhancement, and operational capital.
Where are Ribo's R&D centers located?
Ribo has R&D centers in Suzhou, Beijing, and Gothenburg, Sweden.
